Pharma Mar (PHMMF) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Pharma Mar (NASDAQ:PHMMF) from a buy rating to a hold rating in a report released on Saturday morning.

According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “

Shares of Pharma Mar (NASDAQ:PHMMF) opened at 4.35 on Friday. The stock’s 50 day moving average is $4.46 and its 200 day moving average is $4.04. The stock’s market cap is $1.08 billion. Pharma Mar has a 52-week low of $2.40 and a 52-week high of $4.80.

ILLEGAL ACTIVITY WARNING: This piece was first published by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/09/13/pharma-mar-phmmf-stock-rating-lowered-by-zacks-investment-research.html.

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply